Dr Marcos Alcocer, a lecturer in the School of Biosciences, said: "The whole idea is to trace what we call our immunological profile, the finger print of our immune system which tells us how we react to the things which we are surrounded by.
"Our technology is one step towards the ultimate goal of being able to have a full in-vitro diagnostic test for allergy. What we have to do now is examine the results of our test further and then assess how well it works compared to the gold standard techniques currently used for diagnosis. We will then be in a very good position for commercialisation."
Researchers from The University of Nottingham were also highly commended in the Clinical Impact category of the Da Vinci Awards. A collaboration between Professor Ian Ellis in the University's School of Molecular Medical Sciences and colleagues at Nottingham Trent University and University Hospital Nottingham has led to the development of a breast cancer prognostic tool.
Nottingham Prognostic Index offers a personalised approach to medicine by classifying patients into groups according to their tumour biology, provides information about the patients' most probable survival outcome and guides clinicians in the most appropriate form of treatment.
The tool should reduce the incidence of over-treatment and minimise the harmful side-effects for patients and is due to be commercialised by a spin-out company Nottingham Prognostics.
Anna Seddon, Manager of the Da Vinci Network, said: "The excellent response to the Da Vinci Awards reinforces the importance of building interdisciplinary and inter-institutional collaboration to address critical issues in healthcare. The quality of applicants reflects the wealth of activi
|Contact: Emma Thorne|
University of Nottingham